Detalhe da pesquisa
1.
Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
J Pathol
; 260(5): 514-532, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608771
2.
Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma.
Am J Hematol
; 96(12): 1554-1562, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34424561
3.
The SALT-Readout ASIC for Silicon Strip Sensors of Upstream Tracker in the Upgraded LHCb Experiment.
Sensors (Basel)
; 22(1)2021 Dec 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35009648
4.
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
Am J Hematol
; 94(5): 539-545, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30740766
5.
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Biol Blood Marrow Transplant
; 23(6): 930-937, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28285081
6.
IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.
Mod Pathol
; 27(3): 375-81, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24030741
7.
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Blood
; 120(5): 1095-106, 2012 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-22718837
8.
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma.
Blood
; 119(20): 4597-607, 2012 May 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-22383795
9.
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
J Immunother Cancer
; 12(3)2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38458639
10.
Lymph node vascular-stromal growth and function as a potential target for controlling immunity.
Clin Immunol
; 144(2): 109-16, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22717771
11.
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices.
Cancers (Basel)
; 14(15)2022 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35954426
12.
Development and Performance of a CD8 Gene Signature for Characterizing Inflammation in the Tumor Microenvironment across Multiple Tumor Types.
J Mol Diagn
; 23(9): 1159-1173, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34197924
13.
Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638394
14.
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma.
Br J Haematol
; 143(5): 654-60, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18950461
15.
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
Cancer Res
; 66(15): 7661-7, 2006 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16885367
16.
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Cancer Res
; 65(24): 11345-53, 2005 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16357141
17.
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients.
Clin Lymphoma Myeloma Leuk
; 17(12): 825-833, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29051077
18.
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
J Clin Oncol
; 21(16): 3051-9, 2003 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12837807
19.
CD74 is expressed by multiple myeloma and is a promising target for therapy.
Clin Cancer Res
; 10(19): 6606-11, 2004 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15475450
20.
Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
Leuk Lymphoma
; 56(11): 3065-70, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25754579